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costs and productivity losses were calculated. Costs data were derived from Russian 
cost-of-illness study of depression and registered maximal drug prices list. The 
outcomes were modelled for 3 years period. Costs were converted to EUROs using 
the average weighted exchange rate in 2014 (1€ = 50.815RUR). Sensitivity analysis 
was performed. Results: Agomelatine appeared to be the dominant therapy in 
comparison with branded fluoxetine, sertraline and escitalopram, which allowed 
achieving maximum clinical outcome and utility (2.148 QALY vs 2.097, 2.133 and 
2.119 QALY, respectively) at the lowest costs (€ 1,932 vs € 2,485, € 2,076 and € 2,454). 
Agomelatine remained dominant strategy even when only direct medical costs 
were included into analysis (€ 943 vs € 1,172, € 1,002 and € 1,290). ConClusions: 
Agomelatine was demonstrated to be the rational choice in comparison with other 
branded antidepressants routinely used in Russian health care settings.
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objeCtives: The prevalence of dementia in Singapore is expected to increase with 
an ageing population. With the inclusion of dementia as part of Chronic Disease 
Management Program, more primary care consultations are expected in the poly-
clinic. A Primary Care Dementia Clinic (PCDC) was set up in Ang Mo Kio Polyclinic to 
manage stable patients. The objective of this study is to evaluate the cost-utility of 
dementia care at PCDC compared with specialists’ care at the Memory Clinic (MC) 
and care at other polyclinics. Methods: Stable dementia patients with a Clinical 
Dementia Rating of 1.0 – 3.0 were recruited for the programme. Costs were measured 
from the societal viewpoint, including both direct and indirect costs. To establish 
cost-utility, EQ-5D was used to calculate QALYs. Cost and utility were measured at 
six-months and one-year. The incremental cost-effectiveness ratio was calculated 
by dividing the difference in costs by the difference in QALYs. Results: A total of 
168 dementia patients were recruited for this study. 55 for the PCDC arm and 113 
from the two comparator groups (MC = 82 & Other Polyclinics = 31). Compared 
with care at the Memory Clinic and standard polyclinic care, PCDC was $2,110 
(vs. MC) and $2,335 (vs. Other Polyclinics) lower respectively at six-months. There 
were no statistical differences in one-year costs and QALYs across both compari-
sons. ConClusions: Our analysis found that dedicated dementia care for stable 
patients at the primary care setting reduces societal cost. Expansion of PCDC could 
greatly reduce societal resources without impacting patients’ quality of life.
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objeCtives: To examine the economic burden and health care utilization for patients 
diagnosed with opioid abuse in the U.S. veteran population. Methods: Patients 
diagnosed with opioid abuse (International Classification of Diseases, 9th Revision, 
Clinical Diagnosis codes 965.0x and 965.8x) were identified using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2007 through September 
30, 2012. The first diagnosis date was designated as the index date. A comparison 
cohort was created including patients without opioid abuse using 1:1 propensity 
score matching to control for age, region, gender, index year and baseline Charlson 
Comorbidity Index score. The index date was chosen randomly for the comparison 
cohort to minimize selection bias. Patients in both cohorts were required to be at least 
age 18 years and have continuous medical and pharmacy benefits 1 year pre- and 
1 year post-index date. Study outcomes including health care costs and utilizations 
were compared between the disease and comparison cohorts based on the matched 
sample. Results: After 1:1 matching, 1,652 patients were included in each cohort, 
and the baseline characteristics were well-balanced. More patients with opioid abuse 
had inpatient stays (92.37% vs. 5.08%, p< 0.0001) and emergency room (ER) (73.85% vs. 
11.38%, p< 0.0001), physician office (96.91% vs. 71.91%, p< 0.0001), outpatient (97.46% vs. 
72.82%, p< 0.0001) and pharmacy visits (89.83% vs. 75.00%, p< 0.0001). Higher all-cause 
health care costs were also observed for patients with opioid abuse, including inpa-
tient ($29,203 vs. $1,394, p< 0.0001), ER ($1,155 vs. $112, p< 0.0001), outpatient ($9,193 
vs. $2,665, p< 0.0001), pharmacy ($1,516 vs. $696, p< 0.0001) and total costs ($39,913 
vs. $4,757, p< 0.0001) than for study subjects without opioid abuse. ConClusions: 
During a period of 12 months, VHA patients diagnosed with opioid abuse reported 
higher health care utilization and costs than their matched controls.
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objeCtives: To determine which economic burden outcomes were assessed in 
studies on mental health disorders published in 2014. Methods: An evidence sur-
veillance process was established based on a systematic search of PubMed, incor-
porating all studies published from 2010 and updated weekly, with a final search on 
1 June 2015. Abstracts identified by the search for costs or resource use outcomes 
in mental health disorders were identified. Articles were included if they reported 
results from a primary research study or economic model. Economic outcomes were 
identified, where possible, from the abstract alone. Results:: The economic burden 
search identified 1,870 articles published in 2014, with 968 meeting the inclusion 
criteria for any disease. Of these, 76 (8%) were in mental health disorders. The most 
commonly researched disorders were drug, tobacco or alcohol abuse (25 articles), 
followed by depression (17), dementia (7) and schizophrenia (8). The USA was the 
most common setting, based on abstract text or author affiliations (31 articles), fol-
(p< 0.001). According to the QLS MCID, 49% of patients receiving AOM were classified 
as responders vs. 42% of patients receiving PP. For the CGI-S assessment, 52% vs. 34% 
were responders for AOM and PP, respectively. In both assessments, AOM was the 
economically dominant therapeutic option over PP. Univariate sensitivity analyses 
confirmed these findings, the main drivers being cost of inpatient and outpatient 
services. ConClusions: AOM was found to provide superior clinical benefits and 
cost savings compared to PP in all analyses, representing good economic value in the 
maintenance treatment of schizophrenia in the UK.
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objeCtives: We analyzed cost effectiveness of buprenorphine/naloxone combina-
tion and sustained release (SR) morphine when compared to methadone in patients 
treated for opioid dependence in Slovenia. To compare the expected costs of treatment 
with buprenorphine/naloxone combination and SR morphine, we also performed 
cost-minimization analysis. Methods: We adapted a micro-simulation decision 
model to the real-life conditions in Slovenia by using locally-specific data for main-
tenance treatment costs of buprenorphine/naloxone, SR morphine, and methadone 
with the average dose of treatment set at 10.68 mg/day for buprenorphine/naloxone, 
592 mg/day for SR morphine, and 82 mg/day for methadone. All other direct costs 
were based on COBRA (Cost-Benefit and Risk Appraisal of Substitution Treatment 
in Routine) study and adjusted to conditions of the local jurisdiction. Clinical effi-
cacy data for all three treatment options were derived from published literature; in 
cost-minimization analysis, we assumed that buprenorphine/naloxone combination 
and SR morphine were clinically equivalent. Main outcome measures were costs, 
gains in quality adjusted life years (QALYs), and incremental cost-effectiveness ratios 
(ICERs). Results: Our model has shown that under the base case scenario, buprenor-
phine/naloxone dominated methadone (by saving € 60 and gaining 0.153 QALY over 
one year); when comparing SR morphine and methadone, the resulting ICER was 
€ 5,434 per QALY. Cost-minimization analysis revealed lower treatment costs with 
buprenorphine/naloxone combination than those with SR morphine by 45% (€ 488 per 
year), with treatment costs of buprenorphine/naloxone and SR morphine accounting 
for 28% and 41% of total direct medical costs, respectively. The sensitivity analysis 
showed robustness of our findings. ConClusions: Results of our study suggest that 
treating patients with buprenorphine/naloxone combination instead of methadone 
or SR morphine appears to be cost-saving in Slovenia. This result is particularly rel-
evant for implementation of treatment guidelines and for those patients who can be 
prescribed as an intervention of choice either buprenorphine/naloxone combination, 
SR morphine or methadone.
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objeCtives: Opioid dependence is a serious and costly medical condition that 
can occur with regular opioid use. We conducted a systematic review of published 
model-based economic evaluations of drug substitution therapy in treating non-
medical opioid dependence. Methods: Literature searches were conducted in 
March 2015 in 8 electronic databases and supplemented by hand-searching refer-
ence lists and searches on 6 health technology assessment (HTA) agency websites. 
The selection criteria included: A population dependent on opioids and receiving 
opioid substitution therapy or maintenance therapy. The intervention included any 
pharmacological maintenance therapy and the comparator included any pharmaco-
logical maintenance regimen, including placebo or no treatment. The outcomes and 
study types included health economic models of any type. Results: After removal 
of duplicates, 2,163 citations were retrieved, of which 63 progressed to full-text 
review. Of these, 19 publications of 18 unique models were included in the review. 
These 18 models used a wide range of modelling approaches, including Markov 
models (n= 4), decision tree with Monte Carlo simulations (n= 4), decision analysis 
(n= 3), dynamic transmission models (n= 3), decision tree (n= 1), cohort simulation 
(n= 1), Bayesian (n= 1), and Monte Carlo simulations for sensitivity analysis (n= 1). 
Time horizons ranged from 6 months to a lifetime. The most common evaluation 
was cost-utility analysis reporting cost per quality-adjusted life-year (n= 11), fol-
lowed by cost-effectiveness analysis (n= 4), budget impact analysis/cost comparison 
(n= 2) and cost-benefit analysis (n= 1). Countries modelled were the US (n= 11), UK 
(n= 4), Spain (n= 1), Vietnam (n= 1) and New Zealand (n= 1). A range of perspectives 
were modelled, including societal and healthcare systems. ConClusions: This 
review identified 8 different modelling structures with a range of perspectives, 
time horizons and inputs, illustrating that there is no single preferred approach. 
Further research is needed into the advantages and disadvantages of the different 
modelling approaches in this disease area.
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objeCtives: To evaluate the cost effectiveness of agomelatine versus branded 
fluoxetine, sertraline and escitalopram for treatment of major depressive disor-
ders in adults in Russia. Methods: We have adapted published Markov model 
of major depression disorder. It consisted of 4 different health states (depression, 
remission, well-being and death). Cycle length was 4 weeks. Transition probabili-
ties and utilities were taken from the international published research data. Direct 
